These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24653483)

  • 1. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
    England R; Maddocks M; Manderson C; Zadora-Chrzastowska S; Wilcock A
    BMJ Support Palliat Care; 2011 Dec; 1(3):349-51. PubMed ID: 24653483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
    Überall MA
    MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
    Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
    Nalamachu SR; Parikh N; Dillaha L; Rauck R
    J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients.
    Kosugi T; Hamada S; Takigawa C; Shinozaki K; Kunikane H; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    J Pain Symptom Manage; 2014 Jun; 47(6):990-1000. PubMed ID: 24099893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.
    Rauck R; Parikh N; Dillaha L; Barker J; Stearns L
    Pain Pract; 2015 Jul; 15(6):554-63. PubMed ID: 25060406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation.
    Takigawa C; Goto F; Tanda S; Shima Y; Yomiya K; Matoba M; Adachi I; Yoshimoto T; Eguchi K
    Jpn J Clin Oncol; 2015 Jan; 45(1):67-74. PubMed ID: 25381384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fentanyl buccal tablet for the treatment of cancer-related breakthrough pain.
    Mercadante S
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):9-13. PubMed ID: 25359295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
    Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
    J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.